Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice

Jung, Hoe‐Yune; Kim, Bobae; Ryu, Hye Guk; Ji, Yosep; Park, Soyoung; Choi, Seung Hee; Lee, Dohyun; Lee, In Kyu; Kim, Munki; Lee, You Jeong; Song, Wonkyong; Lee, Young Hee; Choi, Hyung Jin; Hyun, Chang K.; Holzapfel, Wilhelm H.; Kim, Kyong‐Tai

doi:10.1111/dom.13284

Cited by 11 publications

(7 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, a recent study by Jung et al . [36] reported that amodiaquine, an antimalarial agent, has a potential to concurrently activate PPARα and γ. The authors showed that amodiaquine has a potential to improve insulin resistance and lipid metabolism in diabetic mice model [36].…”

Section: An Update On the New Pparα/γ Dual Agonists Being Exploredmentioning

confidence: 99%

“…[36] reported that amodiaquine, an antimalarial agent, has a potential to concurrently activate PPARα and γ. The authors showed that amodiaquine has a potential to improve insulin resistance and lipid metabolism in diabetic mice model [36]. Intriguingly, amodiaquine not only ameliorated insulin resistance, hyperlipidemia and fatty liver; but, also decreased the body weight gain in high-fat diet-induced obese and genetically modified obese/diabetic mice [36].…”

Section: An Update On the New Pparα/γ Dual Agonists Being Exploredmentioning

confidence: 99%

See 1 more Smart Citation

A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia

Balakumar¹,

Mahadevan

Sambathkumar³

2019

CMP

View full text Add to dashboard Cite

Background:Diabetes mellitus and concomitant dyslipidemia, being referred to as ‘diabetic dyslipidemia’, are the foremost detrimental factors documented to play a pivotal role in cardiovascular illness. Diabetic dyslipidemia is associated with insulin resistance, high plasma triglyceride levels, low HDL-cholesterol concentration and elevated small dense LDL-cholesterol particles. Maintaining an optimal glucose and lipid levels in patients afflicted with diabetic dyslipidemia could be a major task that might require a well-planned diet-management system and regular physical activity, or otherwise an intake of combined antidiabetic and antihyperlipidemic medications. Synchronized treatment which efficiently controls insulin resistance-associated diabetes mellitus and co-existing dyslipidemia could indeed be a fascinating therapeutic option in the management of diabetic dyslipidemia. Peroxisome proliferator-activated receptors α/γ (PPARα/γ) dual agonists are such kind of drugs which possess therapeutic potentials to treat diabetic dyslipidemia. Nevertheless, PPARα/γ dual agonists like muraglitazar, naveglitazar, tesaglitazar, ragaglitazar and aleglitazar have been reported to have undesirable adverse effects, and their developments have been halted at various stages. On the other hand, a recently introduced PPARα/γ dual agonist, saroglitazar is an emerging therapeutic agent of glitazar class approved in India for the management of diabetic dyslipidemia, and its treatment has been reported to be generally safe and well tolerated.Conclusion:Some additional and new compounds, at initial and preclinical stages, have been recently reported to possess PPARα/γ dual agonistic potentials with considerable therapeutic efficacy and reduced adverse profile. This review sheds light on the current status of various PPARα/γ dual agonists for the management of diabetic dyslipidemia.

show abstract

Section: An Update On the New Pparα/γ Dual Agonists Being Exploredmentioning

confidence: 99%

Section: An Update On the New Pparα/γ Dual Agonists Being Exploredmentioning

confidence: 99%

A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia

Balakumar¹,

Mahadevan

Sambathkumar³

2019

CMP

View full text Add to dashboard Cite

show abstract

“…Normal diet (D12450B; 3.84 kcal/g; 10% kcal from fat consisting of 25 g/kg soybean oil and 20 g/kg lard) and high-fat diet (HFD) (D12492; 5.24 kcal/g; 60% kcal from fat consisting of 25 g/kg soybean oil and 245 g/kg lard) were purchased from Research Diet, New Brunswick, NJ, USA. All mice except those administered the normal diet (ND) received a HFD for 14 weeks to induce hepatic steatosis [29][30] . From the 8th week, the HFD-fed mice were subcutaneously injected with 2 mg/kg CORT (Sigma-Aldrich Corp., St. Louis, MO, USA) once daily for 7 weeks to promote glucocorticoid-induced hepatic steatosis [31][32] .…”

Section: Animal Experimentsmentioning

confidence: 99%

Novel insights into the effect of Xiaoyao san on corticosterone-induced hepatic steatosis: inhibition of glucocorticoid receptor/perilipin-2 signaling pathway

Gong

Wang

et al. 2022

Acupuncture and Herbal Medicine

View full text Add to dashboard Cite

Objective:Xiaoyao san (XYS) is a classic traditional Chinese medicinal formula. It has been clinically administered to regulate liver function. However, its mechanisms in glucocorticoid-induced hepatic steatosis are unknown. This study aimed to investigate whether XYS protects against corticosterone (CORT)-induced hepatic steatosis, and to explore its mechanism.Methods:High-fat diet mice induced with hepatic steatosis by 2 mg/kg CORT were administered 2.56 g/kg or 5.12 g/kg XYS daily for 7 weeks. The effects of XYS on hepatic steatosis in mice were evaluated by H&E and Oil Red O staining and by measuring their plasma lipids (triglyceride, total cholesterol, and free fatty acids). The mechanism of XYS against hepatic steatosis was investigated by network pharmacology, immunohistochemistry, western blotting, and gain-of-function/loss-of-function experiments.Results:XYS alleviated CORT-induced steatosis, decreased plasma lipids, and inhibited glucocorticoid receptor (GR) activation in the liver. Network pharmacology data indicated that XYS may have mitigated hepatic steatosis via GR which mediated adipose differentiation-related protein (ADFP). Gain-of-function/loss-of-function experiments in vitro confirmed that GR positively regulated ADFP expression.Conclusions:XYS ameliorated CORT-induced hepatic steatosis by downregulating the GR/ADFP axis and inhibiting lipid metabolism. Our studies implicate that XYS is promising as a therapy for CORT-induced hepatic steatosis, and lay the foundation for designing novel prophylactic and therapeutic strategies on CORT-induced hepatic steatosis.

show abstract

“…Dietary intervention by phytochemicals in the prevention and treatment of metabolic syndrome has been reported in numerous studies. [47][48][49][50][51][52][53] Therefore, this work aims to investigate the health benefit of quercetin for ameliorating hepatic fat accumulation in HFD-induced obese mice. Firstly, HFD mouse models were established to examine the protective effects of quercetin on hepatic steatosis and inflammation.…”

Section: Introductionmentioning

confidence: 99%

Quercetin ameliorates hepatic fat accumulation in high-fat diet-induced obese mice via PPARs

et al. 2023

View full text Add to dashboard Cite

show abstract

Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice

Cited by 11 publications

References 58 publications

A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia

A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia

Novel insights into the effect of Xiaoyao san on corticosterone-induced hepatic steatosis: inhibition of glucocorticoid receptor/perilipin-2 signaling pathway

Quercetin ameliorates hepatic fat accumulation in high-fat diet-induced obese mice via PPARs

Contact Info

Product

Resources

About